Grifols SA operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Grifols SA with three other
pharmaceutical manufacturers in Europe:
sales of 258.45 billion Russian Rubles [US$3.82 billion]
of which 78%
Lonza Group AG
(5.11 billion Swiss Francs [US$5.13 billion]
of which 47%
was Specialty Ingredients), and
based in Belgium
(4.53 billion Euro [US$5.17 billion]
of which 100%
Grifols SA reported sales of 4.32 billion Euro (US$4.93 billion)
December of 2017.
increase of 6.6%
versus 2016, when the company's sales were 4.05 billion Euro.
Sales at Grifols SA have increased during each of the previous five years
(and since 2012, sales have increased a total of 65%).
Sales of Bioscience saw an increase
6.2% in 2017, from
3.23 billion Euro to 3.43 billion Euro.
Not all segments of Grifols SA experienced an increase in sales in 2017:
sales of Others/raw Materials fell 69.0% to 18.26 million Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).